The effect of selegiline on function in stroke patients

The effect of selegiline on functional and cognitive recovery in stroke patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200719048136N1

Enrollment

Registered

2020-09-16

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Brain stem stroke syndrome

Interventions

Intervention 1: Intervention group: receive selegiline (10 mg) orally twice daily for two months in addition to the routine treatments. All drugs are manufactured by Zahravi Company. Intervention 2: C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: primery or hemoragic ischemia brain stroke

Exclusion criteria

Exclusion criteria: progressive brain stoke brain tumor subdural hematoma multiple sclorosis Multi-infarct dementia epilepsy

Design outcomes

Primary

Measure	Time frame
Cognitive function. Timepoint: Two weeks after the intervention. Method of measurement: Neurologic examination.	—

Secondary

Measure	Time frame
Motor function. Timepoint: Two weeks after the intervention. Method of measurement: Neurologic examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNahid Jivad

Shahre-kord University of Medical Sciences

Jivad@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026